cancer at the time of presentation. The clinicopathological characteristics of these patients are shown in Table 1 . Patients were categorized into two clinical groups: 50 patients with Dukes A, B or C tumours who underwent a definitive surgical resection; and 42 patients with advanced disease characterized by distant metastases at presentation i.e. 'Dukes D' (n = 29), or local pelvic recurrence (n = 13). Additional serum samples were obtained in 27 patients; 6-8 weeks following definitive surgery in 15 patients, and at variable times (median 5 weeks) during tumour progression in a further 12 patients. As nutritional status is known to influence circulatory levels of the IGFs and their binding proteins (Thissen et al, 1994) , cancer patients were also categorized by nutritional status using the following criteria. Malnutrition was defined when at least two of the following were present in an individual patient: malnourished by global subjective assessment; body mass index less than 20 kg m -2 ; mean arm circumference < 27 cm in males or < 26 cm in females; or albumin < 33 mg l -1 (modified from Hammerlid et al, 1998) . The control group comprised serum samples obtained from 57 individuals (median age = 60 (range 29-87) years, 20 males, 37 females) with normal colonoscopic findings and no history of previous colorectal neoplasia. The study was approved by the Local Ethics Committee for South Manchester Health Authorities.
Clinicopathological parameters
Tumour stage was determined both clinically and on pathological evaluation. Surgically resected specimens were staged in accordance with Dukes classification (Turnbull et al, 1967) and graded by the degree of differentiation (well, moderate, poor) in accordance with the WHO classification (Jass and Sobin, 1989) . For primary tumours treated by curative resection, size was the maximum tumour diameter and the site was classified as right colon (proximal to splenic flexure), left colon (splenic flexure to rectosigmoid junction) and rectum. The presence and extent of advanced disease (all had at least hepatic metastases) was determined using computerized tomographic (CT) or magnetic resonance (MR) scanning. Pelvic recurrence was confirmed by a combination of CT or MR scanning and examination under anaesthesia with biopsy for histological diagnosis.
Assays
IGF-I was measured, following acid-alcohol extraction, by an established radioimmunoassay (RIA) using a polyclonal rabbit antiserum (R557A) raised against purified human IGF-I (Taylor et al, 1990; Toogood et al, 1998) . Serum IGF-II was determined using a commercially available immunoradiometric assay (IRMA) kit (DSL, Webster, Texas, USA). IGFBP-2 and IGFBP-3 were measured using an RIA and IRMA, respectively (DSL). All samples were determined blind to cancer status and stage, and were assayed in triplicate. The inter-assay coefficients of variation (CV) at low, medium and high analyte levels were less than 10% for all four assays, with intra-assay CVs less than 5%. The sensitivities for IGF-I, IGF-II, IGFBP-2, and IGFBP-3, were 14 µg l -1 , 15 µg l -1 , 5 µg l -1 and 0.5 mg l -1 , respectively. Carcinoembryonic antigen (CEA) was measured using a two-site (sandwich) chemilumuninescence system (Chiron Diagnostics, Halstead, UK). The threshold definition for an elevated CEA level was 5 ng ml -1 , with an analytical sensitivity of 0.5 ng ml -1 .
Statistical analysis
As IGF ligands and binding proteins are age-and sex-dependent (Rajaram et al, 1997) , absolute concentrations were converted to standard deviation scores (SDS) (SDS = (x -X)/SD: x = measured value, X = mean of normal values for age and sex of an individual, SD = standard deviation). Normal reference means and standard deviations were generated from an in-house dataset of 295 healthy individuals using the above assays (see Appendix for details). Differences in mean SDS were compared using Students t-test for independent means, paired t-tests, and one-way ANOVA as appropriate. Correlations were described by Pearsons coefficient (r). Tests were two-sided and a P-value less than 0.05 was considered to indicate statistical significance using SPSS 9.0 (Superior Performing Software Systems, Chicago, USA) for computations.
RESULTS

Validation of controls
For the 57 individuals with a normal colonoscopy, IGFBP-3 was significantly correlated with IGF-I (r = 0.38, P = 0.005) and IGF-II (r = 0.85, P < 0.001), similar to correlations seen in the normal reference data (see Appendix). The absolute concentrations for serum IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in the 57 controls fell within the 90% predictive intervals as defined by the age-sex regression equations for normals in 96%, 100%, 98%, and 95% of values, respectively.
Cases vs controls
When examined for all 92 patients with colorectal cancer, mean IGF-II SDS were marginally elevated compared with normal colonoscopy controls (mean ± SEM = 0.46 ± 0.18 vs 0.01 ± 0.09, P = 0.06). There was no significant trend in IGF-II SDS across the Dukes stages (one-way ANOVA) but when analysed separately, mean SDS were significantly elevated in Dukes A (1.43 ± 0.34, Tumour differentiation quoted for the 50 patients undergoing primary definitive resection P < 0.001) and Dukes B (0.93 ± 0.29, P < 0.001) patient groups ( Figure 1A) . A number of patients with Dukes C and advanced disease had greatly elevated IGF-II SDS but overall, the means were not raised. On the other hand, mean IGFBP-2 SDS was significantly raised in the total cancer patient group compared with controls (1.37 ± 0.12 vs 0.17 ± 0.10, P < 0.0001). When considered by stage of disease, there was a significant trend toward increasing IGFBP-2 SDS from early to advanced disease (one-way ANOVA, P < 0.0001), with significantly elevated means in Dukes B (1.03 ± 0.15, P < 0.001), Dukes C (1.13 ± 0.22, P < 0.001) and advanced disease (1.89 ± 0.16, P < 0.0001) compared with controls ( Figure 1B) .
For all cases, there were no differences either in mean IGF-I SDS compared with controls (-0.19 ± 0.13 vs 0.17 ± 0.12, P = 0.2) or mean IGFBP-3 SDS and controls (0.88 ± 0.20 vs 0.56 ± 0.14, P = 0.6). When analysed by stage, there were no differences in mean IGF-I and IGFBP-3 SDS vs controls, with the exception that mean IGF-I SDS was significantly reduced in patients with advanced disease in whom malnutrition was prevalent (see below) (-0.59 ± 0.18 vs 0.17 ± 0.12, P = 0.001).
Effect of nutritional status
Malnutrition was present in six of 34 (18%) Dukes B patients, three of 13 (23%) Dukes C patients, and 19 of 42 (45%) patients with advanced disease. For all malnourished cancer patients, mean SDS were significantly reduced for IGF-I (malnourished vs controls = -0.87 ± 0.22 vs 0.19 ± 0.15, P < 0.001), IGF-II (-0.48 ± 0.32 vs 1.04 ± 0.20, P < 0.001), and IGFBP-3 (0.06 ± 0.42 vs 1.26 ± 0.23, P = 0.04), but elevated for IGFBP-2 (1.68 ± 0.22 vs 1.16 ± 0.13, P = 0.04). SDS values by nutritional status and disease status are shown in Table 2 .
When the analysis was limited to well-nourished individuals, patterns of mean IGF-II and IGFBP-2 SDS for cases and controls were similar to the overall cohort. Of interest, however, after exclusion of malnutrition, mean IGF-II SDS were more significantly elevated in patients with Dukes B (1.18 ± 0.34, P < 0.001), and also significantly elevated in Dukes C patients (0.63 ± 0.56, wide variance, P = 0.05) compared with colonoscopy controls.
Relationship of IGF-II and IGFBP-2 and pathological characteristics
As both serum IGF-II and IGFBP-2 levels were elevated in cancer cases, we explored their relationships with a number of clinicopathological characteristics among the 50 patients who underwent definitive surgical resection for Dukes A, B and C tumours (Table 3) . There were no associations between IGF-II SDS and tumour size, differentiation, nodal status, and anatomic site, although there was a tendency for higher IGF-II SDS in small cancers compared with larger cancers. In contrast, IGFBP-2 SDS increased with increasing tumour size (P = 0.01), but similar to IGF-II showed no associations with degree of differentiation, nodal status or anatomic site.
Serial IGF-II and IGFBP-2 levels
We analysed serum IGF-II and IGFBP-2 values in 27 cancer patients before and after, or during treatments. In 15 patients undergoing curative resection for Dukes A, B and C tumours, there was a significant reduction in mean IGFBP-2 6-8 weeks following curative resection (mean ± SEM = 1011 ± 88 vs 860 ± 65 µg l -1 , paired t-test, P = 0.04), but no differences in mean IGF-II values. In a further 12 patients with persistent or progressive cancer, follow-up samples demonstrated elevated IGFBP-2 levels in eight (Figure 2 ).
Tumour marker characteristics of IGFBP-2
We tested the potential tumour marker characteristics of IGFBP-2 SDS taking an arbitrary cut-off for elevated IGFBP-2 at ≥ +2 SDS. IGFBP-2 SDS were therefore elevated in 26 (28%) cases while serum CEA was elevated (≥ 5 ng ml -1 ) in 42 (46%). IGFBP-2 SDS were significantly correlated with CEA (r = 0.49, P < 0.001), but of the 26 patients with elevated IGFBP-2 SDS, seven had advanced disease without elevated CEA values, suggesting that IGFBP-2 SDS may have independent predictive qualities (quadrant M in Figure 3 ). We therefore calculated sensitivities, 1.08 ± 0.38 0.87 ± 0.15 ≥ 5.5 cm (n = 16) 0.56 ± 0.39 P = n.s. 1.33 ± 0.22 P = 0.01 Differentiation Well (n = 11) 1.34 ± 0.23 0.79 ± 0.21 Moderate/poor (n = 37/2) 0.98 ± 0.25 P = n.s. 0.85 ± 0.14 P = n.s.
Nodal status
No (n = 37) 1.09 ± 0.24 0.80 ± 0.14 Yes (n = 13) 0.96 ± 0.44 P = n.s. 0.93 ± 0.19 P = n.s. Site distribution specificities, positive and negative predictive values for IGFBP-2 SDS alone, CEA alone, and both together, against three main endpoints: metastasis alone; local recurrence alone; and metastasis and recurrence combined (Table 4) . By itself, the sensitivities for IGFBP-2 SDS were modest at 55%, 46% and 52%, respectively. In combination with CEA, however, the sensitivities for the three endpoints increased substantially to 90%, 77%, and 86%, respectively.
DISCUSSION
This study has focused on the relationships of serum IGF-II and IGFBP-2 with colorectal cancer, and found that age-sex adjusted IGF-II values are significantly raised in patients with early cancers but seemingly not in advanced disease, and age-sex adjusted IGFBP-2 values increased significantly from early to advanced disease, and on average, were two standard deviations greater than controls in patients with metastatic and recurrent disease. Age-sex adjusted IGFBP-2 was also associated with tumour size and fell significantly in patients following curative tumour resection, suggesting that the circulating IGFBP-2 levels reflect tumour load. The sensitivities of serum IGFBP-2 alone as a marker of distant metastasis and/or recurrence were modest but increased substantially in combination with carcinoembryonic antigen (CEA). There were no associations between serum IGF-I and IGFBP-3, and the presence of cancer, but all four IGF-related peptides were significantly influenced by nutritional status. Two small studies, from the same institute, have previously reported elevated IGF-II and IGFBP-2 levels in patients with colorectal cancer measured semi-quantitively from immunoblots (el Atiq et al, 1994; Baciuchka et al, 1998) . In the present study, the use of radioimmunoassays and immunoradiometric assays afforded us the opportunity to investigate a large number of cases and controls, make adjustments for predicted age-and sex-related changes, and undertake subanalyses to evaluate the influences of different clinicopathological factors, nutritional status and treatment. Furthermore, the current study design carefully chose individuals with normal colonoscopic findings as controls, as serum IGF-II and IGFBP-2 levels may be elevated even in the presence of occult benign colorectal tumours (Renehan et al, 2000a) .
The increase in serum IGF-II observed in patients with Dukes A and B colorectal cancers extends our observations that serum IGF-II is significantly raised in individuals with colorectal adenomas (Renehan et al, 2000a) . At first glance, the lack of an IGF-II increase in patients with more advanced disease appears paradoxical. The paradox remained even after adjustment for nutritional status (malnutrition was prevalent among patients with more advanced disease and is a negative regulator of IGF-II) and suggests that there may be a down-regulation or post-transcriptional modification of IGF-II peptide expression with advancing disease. Consistent with the latter hypothesis, IGF-II immunohistochemical expression is absent in normal colonic epithelium, almost universally positive in adenomas (Renehan et al, 2000a ), but present in only half of adenocarcinomas examined with high positivity scores limited to well differentiated cancers (observations from our laboratory). The relevance of raised serum IGF-II is unknown, but as IGF-II is both mitogenic and anti-apoptotic, it is generally perceived to be a factor favouring tumour progression (Macaulay, 1992) . In support of this view, Kawamoto et al (1998) have observed that IGF-II immunopositivity predicts for poor prognosis in colorectal cancers.
The finding of raised serum IGFBP-2 in colorectal cancer patients is in accordance with other reports describing elevated IGFBP-2 levels in various malignancies including lung (Reeve et al, 1990) , ovary (Kanety et al, 1996) , prostate (Cohen et al, 1993; Ho and Baxter, 1997 ), Wilm's tumour (Zumkeller et al, 1993) and childhood leukaemia (Muller et al, 1994; Mohnike et al, 1996; Wex et al, 1998) . In the absence of a clearly understood physiological role for IGFBP-2, these collective observations suggest that this binding protein may have a special role in malignancy. At a tissue level, through sequestration of ligand from its receptor, the effect of IGFBP-2 on the mitogenic action of IGF-I and IGF-II is generally considered inhibitory (Jones and Clemmons, 1995) , and this has been shown to be the case in some IGF-responsive colonic carcinoma cell lines (Hoeflich et al, 1998) . However, Hoeflich and colleagues (2000) have also reported a stimulatory effect of IGFBP-2 via IGF-I receptor-independent mechanisms in adenocortical tumour cells, and whether these pathways exist in colonic cancers is not yet known.
An alternative and attractive hypothesis for the role of increased IGFBP-2 in malignancy is that it serves as a storage pool for IGF-II (which binds with greater affinity than IGF-I) in the microenvironment of tumour cells. It has recently been recognized that an IGF-II/IGFBP-2 complex may partly bind to the extracellular matrix (ECM) (Arai et al, 1996) from where IGF-II may be liberated by proteolysis. A serine protease capable of degrading IGFBP-2 has been described, which leads to a reduction of the IGF binding capacity and liberation of its ligands into the pericellular environment (Gockerman and Clemmons, 1995) . Based on this hypothetical model, the increased IGFBP-2 in the circulation may provide a reservoir for ECM-bound IGF/IGFBP-2 complexes in the vicinity of tumour cells, and thus the presence of elevated circulating IGFBP-2 could enhance tumour growth and progression.
We explored the characteristics of serum IGFBP-2 as a potential tumour marker and its relationship with serum CEA. The sensitivity of 72% for CEA detecting both distant metastases and recurrences combined is similar to values (66-85%) found in other studies (Wang et al, 1994; Wolf and Cohen 1997) . Consistent with other studies (Moertel et al, 1993) , we also found that the sensitivity of CEA to detect local pelvic recurrences was lower relative to its ability to detect distant metastases. Using a cut-off of +2 SDS, the sensitivities of IGFBP-2 alone for the detection of distant metastases and/or recurrences were modest but increased substantially when combined with CEA. This suggests a potential role for IGFBP-2 as an adjunct to CEA in monitoring patients with colorectal cancer. At a time when there is increasing evidence that intensive surveillance with early detection of recurrent and metastatic disease offers opportunities to improve survival (Renehan and O'Dwyer, 2000) , prospective studies are now required to assess the benefits of serial IGFBP-2 monitoring (with CEA) in patients who have undergone curative treatment for colorectal cancer.
Whereas the characteristics of serum IGF-II and IGFBP-2 are best described as tumour markers, the characteristics of serum IGF-I and IGFBP-3 are best described as predictive for cancer risk. A number of recent epidemiological studies have demonstrated associations between circulating IGF-I and IGFBP-3 levels and cancer risk in various malignancies (Chan et al, 1998; Hankinson et al, 1998; Ma et al, 1999) . Specifically for colorectal cancer, Ma and colleagues (1999) have reported that high-normal range IGF-I values and low-normal range IGFBP-3 values predict for subsequent cancer development. We have recently shown that the same profile (high IGF-I/low IGFBP-3) predicts for 'high-risk' adenomas (Renehan et al, 2000b) but the current study was not specifically designed to assess cancer risk, as confounding factors such as altered nutritional status were expected (and subsequently demonstrated) in our cohort. For these reasons, we caution against drawing conclusions about the relationships of serum IGF-I, IGF-II and IGFBP-3 and colorectal cancer risk from studies using cross-sectional designs (Manousus et al, 1999) .
This study, together with our previous observations in individuals with colorectal adenomas, have shown that there is a characteristic profile for serum IGF-II and IGFBP-2 from pre-malignant adenomas through early carcinomas to metastatic colorectal disease. We have speculated that these distinctive patterns may provide insight into underlying biological mechanisms. The potential of serum IGFBP-2 as a tumour marker in colorectal cancer has been demonstrated, but large prospective studies are required before definitive conclusions regarding its use in clinical practice can be drawn.
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